IMS Connect – June 5, 2026

European panel publishes guidance on outpatient delivery of bispecifics Using a modified Delphi approach, a panel of European experts generated consensus recommendations on safe and effective outpatient step-up-dosing of bispecific antibody (bsAb) therapies for patients with multiple myeloma (MM). The report, published in the European Journal of Haematology, also provides guidance on care transition from academic … Continued

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events

  • This field is for validation purposes and should be left unchanged.